Insider and Congress filings

Edwards Lifesciences Corporation (EW)

Medical Devices, listed on NYSE.

S&P 500321 insider transactions96 Congress tradeslast filed Nov 10, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Nov 4, 2026

Edwards Lifesciences beat by 7.5% on adjusted EPS.

$0.80 a share against a $0.74 consensus. Revenue $1.72B against $1.68B, a beat of 2.1%.

EPS

Reported$0.80
Consensus$0.74

Revenue

Reported$1.72B
Consensus$1.68B

Beat 5Miss 1

Next report Feb 9, 2027. Consensus $0.66 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

3

of the 97 fund managers GetSignal tracks list Edwards Lifesciences among their largest positions. Holocene Advisors held the most, $284.0M.

Every manager

Insider tradesForm 4 · 20 open-market filings shown

20 open-market sales, 9 of them under 10b5‑1 plans.

May 15, 2026Nov 10, 2026

SalesSales under a plan

9 of 20 under a plan

Filed the same day as the trade, at the median. Form 4 is due within two business days.

Every filing
Companyfrom the company's filings and listing, as of Nov 10, 2026

About Edwards Lifesciences Corporation

Exchange
NYSE
Sector
Healthcare
Industry
Medical - Devices
Chief executive
Bernard J. Zovighian
Employees
16,000
Listed since
Mar 27, 2000
Market value
$60.4B
Price to earnings (12 mo)
59.2
Net income per share, as reported (12 mo)
$1.77
Dividend yield
-

www.edwards.com

Earnings6 reported quarters · next on Feb 9, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 4, 2026$0.80$0.74$1.7B$1.7BEPS beatRevenue beat
Q2 FY2026reported Jul 23, 2026$0.78$0.74$1.7B$1.7BEPS beatRevenue beat
Q1 FY2026reported Apr 23, 2026$0.78$0.73$1.6B$1.6BEPS beatRevenue beat
Q4 FY2025reported Feb 10, 2026$0.58$0.62$1.6B$1.5BEPS missRevenue in line
Q3 FY2025reported Oct 30, 2025$0.67$0.60$1.6B$1.5BEPS beatRevenue beat
Q2 FY2025reported Jul 24, 2025$0.67$0.62$1.5B$1.5BEPS beatRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on EW yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on EW, newest first
FirmRatingTargetActionDate
Truist SecuritiesBuy$118Raised from $113
Wells FargoOverweight$113Target set
MizuhoOutperformrated Jul 15, 2026$120Target set
UBSBuy$110Target set
Piper SandlerOverweight$101Raised from $100
LeerinkOutperform$101Target set
RBC CapitalOutperform$110Raised from $100
Evercore ISIOutperform$100Raised from $93
BTIGBuy$110Raised from $100
BarclaysOverweight$110Raised from $104
CanaccordHold$85Cut from $87
Goldman SachsBuy$95Cut from $108
StifelBuy$110Raised from $105
BairdNot stated$90Raised from $87

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice. A rating with its own date under it is the firm's latest from the past 120 days, where the note stated none.

4 other firms rated EW in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 11, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Mar 26, 2026

Executive pay

Mr. Zovighian’s pay as CEO came to $17.5M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Mr. ZovighianChief Executive Officer and Director$1.2M$7.2M$9.1M$17.5M
Mr. UllemCorporate Vice President, Chief Financial Officer$808K$2.2M$3.0M$6.1M
Mr. ChopraCorporate Vice President, Transcatheter Mitral and Tricuspid Therapies$671K$1.8M$2.3M$4.7M
Mr. BoboCorporate Vice President, Strategy & Corporate Development$760K$1.4M$2.1M$4.2M
Ms. BrülsCorporate Vice President, EMEACLA$727K$1.0M$2.0M$3.7M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

1,339 institutions reported Edwards Lifesciences shares in 13F filings for Jun 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$5.3B58,789,433+11.8%10.20%
Vanguard Capital Management LLC$3.4B37,615,952-0.3%6.53%
Vanguard Portfolio Management LLC$2.4B26,411,4020.0%4.58%
State Street Corp$2.4B26,321,940+0.1%4.54%
JPMorgan Chase & Co.$2.1B22,783,175+4.8%3.95%
Wellington Management Group LLP$1.5B16,827,967-23.5%2.92%
Geode Capital Management, LLC$1.4B15,437,251+17.5%2.68%
Bank of New York Mellon Corp$1.3B14,084,483-15.9%2.44%
DZ Bank AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main$1.2B13,002,965+1.5%2.26%
Ninety One UK Ltd$1.1B12,337,502-0.5%2.14%
Aristotle Capital Management, LLC$783.9M8,665,712New1.50%
FMR LLC$763.1M8,435,949-41.8%1.46%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings3 managers

Tracked fund managers holding EW

ManagerValueSharesShare of book
Holocene Advisors$284.0M3,139,2850.6%
Woodline Partners$141.1M1,560,0620.4%
OrbiMed$75.5M834,9001.4%

3 of the 97 fund managers we track list EW shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 420 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Daniel J. LippisCVP, TAVRSold · scheduled619$104.25$65KNov 10, 2026filed Nov 10, 20260d
Donald E. Bobo Jr.CVP, Strategy/Corp DevelopmentSold · scheduled48,900$103.05$5.0MNov 9, 2026filed Nov 9, 20260d
Bernard J. ZovighianCEOSold · scheduled · 2 lines23,100$103.02$2.4MNov 9, 2026filed Nov 9, 20260d
Daniel J. LippisCVP, TAVRSold · scheduled619$85.65$53KOct 8, 2026filed Oct 8, 20260d
Daniel J. LippisCVP, TAVRSold · scheduled619$87.51$54KSep 11, 2026filed Sep 11, 20260d
Andrew M. DahlSVP, Corporate ControllerSold544$91.06$50KAug 31, 2026filed Aug 31, 20260d
Annette BrulsCVP, EmeaclaSold2,644$89.98$238KAug 28, 2026filed Aug 28, 20260d
Wayne MarkowitzCVP, JAPACSold1,240$91.47$113KAug 26, 2026filed Aug 26, 20260d
Daveen ChopraCVP, Tmtt, Surgical & IhfmSold · 2 lines31,800$91.02$2.9MAug 26, 2026filed Aug 26, 20260d
Daniel J. LippisCVP, TAVRSold · scheduled619$92.03$57KAug 11, 2026filed Aug 11, 20260d
Wayne MarkowitzCVP, JAPACSold146$86.03$13KJul 30, 2026filed Jul 30, 20260d
Wayne MarkowitzCVP, JAPACSold9,628$85.06$819KJul 28, 2026filed Jul 28, 20260d
Bernard J. ZovighianCEOSold2,921$83.93$245KJul 27, 2026filed Jul 27, 20260d
Daniel J. LippisCVP, TAVRSold · scheduled619$91.70$57KJul 10, 2026filed Jul 10, 20260d
Daniel J. LippisCVP, TAVRSold · scheduled619$91.40$57KJun 30, 2026filed Jun 30, 20260d
Bernard J. ZovighianCEOSold · scheduled523$87.92$46KJun 17, 2026filed Jun 17, 20260d
Andrew M. DahlSVP, Corporate ControllerSold568$86.08$49KMay 29, 2026filed May 29, 20260d
Donald E. Bobo Jr.CVP, Strategy/Corp DevelopmentSold23,145$86.42$2.0MMay 27, 2026filed May 27, 20260d
Daveen ChopraCVP, Tmtt & SurgicalSold1,500$84.60$127KMay 22, 2026filed May 22, 20260d
Donald E. Bobo Jr.CVP, Strategy/Corp DevelopmentSold · 2 lines17,968$81.96$1.5MMay 15, 2026filed May 18, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Daniel J. LippisCVP, TAVROption exercise619Nov 10, 2026
Donald E. Bobo Jr.CVP, Strategy/Corp DevelopmentOption exercise48,900Nov 9, 2026
Bernard J. ZovighianCEOOption exercise23,100Nov 9, 2026
Daniel J. LippisCVP, TAVROption exercise619Oct 8, 2026
Andrew M. DahlSVP, Corporate ControllerTax withholding253Sep 13, 2026
Wayne MarkowitzCVP, JAPACTax withholding568Sep 14, 2026
Wayne MarkowitzCVP, JAPACTax withholding355Sep 11, 2026
Daniel J. LippisCVP, TAVROption exercise619Sep 11, 2026
Daveen ChopraCVP, Tmtt, Surgical & IhfmTax withholding398Sep 11, 2026
Daveen ChopraCVP, Tmtt, Surgical & IhfmOption exercise31,800Aug 26, 2026
Daniel J. LippisCVP, TAVROption exercise619Aug 11, 2026
Wayne MarkowitzCVP, JAPACOption exercise9,628Jul 28, 2026
Bernard J. ZovighianCEOGift320Jul 27, 2026
Annette BrulsCVP, EmeaclaTax withholding109Jul 11, 2026
Daniel J. LippisCVP, TAVROption exercise619Jul 10, 2026
Theodora MistrasCVP, Chief Financial OfficerStock award161,720Jul 9, 2026
Daniel J. LippisCVP, TAVRTax withholding377Jul 7, 2026
Daniel J. LippisCVP, TAVROption exercise619Jun 30, 2026
Daniel J. LippisCVP, TAVROption exercise620May 18, 2026
Daveen ChopraCVP, Tmtt & SurgicalTax withholding7,538May 11, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act20 disclosures of 96 on record · median 30d of the 45 allowed

Congress trades in EW

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Ro KhannaStockSale$1,001 - $15,000+17.1% since the saleEstimated exit price $88.82, close on Mon Aug 3Current price $104.01, close on Tue Nov 10Aug 3, 2026Sep 4, 202632d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000+31.1% since the tradeEstimated entry price $79.34, close on Fri Mar 27Current price $104.01, close on Tue Nov 10Mar 27, 2026Jul 21, 2026116d
Ro KhannaStockPurchase$1,001 - $15,000+23.9% since the tradeEstimated entry price $83.98, close on Fri May 1Current price $104.01, close on Tue Nov 10May 1, 2026Jun 9, 202639d
Ro KhannaStockPurchase$1,001 - $15,000+27.8% since the tradeEstimated entry price $81.38, close on Fri May 15Current price $104.01, close on Tue Nov 10May 15, 2026Jun 9, 202625d
Ro KhannaStockPurchase$1,001 - $15,000+20.2% since the tradeEstimated entry price $86.51, close on Wed May 27Current price $104.01, close on Tue Nov 10May 27, 2026Jun 9, 202613d
Ro KhannaStockSale$1,001 - $15,000+23.6% since the saleEstimated exit price $84.15, close on Fri Apr 24Current price $104.01, close on Tue Nov 10Apr 24, 2026May 11, 202617d
Ro KhannaStockPurchase$1,001 - $15,000+33.1% since the tradeEstimated entry price $78.12, close on Mon Apr 13Current price $104.01, close on Tue Nov 10Apr 13, 2026May 11, 202628d
Ro KhannaStockSale$1,001 - $15,000+30.8% since the saleEstimated exit price $79.50, close on Mon Mar 30Current price $104.01, close on Tue Nov 10Mar 30, 2026Apr 7, 20268d
Ro KhannaStockPurchase$1,001 - $15,000+26.8% since the tradeEstimated entry price $82.02, close on Mon Mar 23Current price $104.01, close on Tue Nov 10Mar 23, 2026Apr 7, 202615d
Ro KhannaStockSale$1,001 - $15,000+33.2% since the saleEstimated exit price $78.10, close on Thu Feb 5Current price $104.01, close on Tue Nov 10Feb 5, 2026Mar 9, 202632d
Josh GottheimerJointStockSale$1,001 - $15,000+20.9% since the saleEstimated exit price $86.02, close on Wed Nov 19, 2025Current price $104.01, close on Tue Nov 10Nov 19, 2025Dec 29, 202540d
Ro KhannaStockSale$1,001 - $15,000+35.6% since the saleEstimated exit price $76.72, close on Tue Oct 7, 2025Current price $104.01, close on Tue Nov 10Oct 7, 2025Nov 6, 202530d
Jefferson ShreveStockSale$50,001 - $100,000+39.1% since the saleEstimated exit price $74.80, close on Mon May 12, 2025Current price $104.01, close on Tue Nov 10May 12, 2025Jun 22, 202541d
Bruce WestermanStockSale$1,001 - $15,000+50.3% since the saleEstimated exit price $69.20, close on Mon Apr 21, 2025Current price $104.01, close on Tue Nov 10Apr 21, 2025May 12, 202521d
Jefferson ShreveStockPurchase$15,001 - $50,000+50.7% since the tradeEstimated entry price $69.00, close on Mon Apr 7, 2025Current price $104.01, close on Tue Nov 10Apr 7, 2025May 8, 202531d
Robert BresnahanStockPurchase$1,001 - $15,000+55.1% since the tradeEstimated entry price $67.07, close on Tue Apr 8, 2025Current price $104.01, close on Tue Nov 10Apr 8, 2025May 8, 202530d
Bruce WestermanStockPurchase$1,001 - $15,000+45.7% since the tradeEstimated entry price $71.39, close on Mon Mar 3, 2025Current price $104.01, close on Tue Nov 10Mar 3, 2025Apr 16, 202544d
Ro KhannaStockPurchase$1,001 - $15,000+51.8% since the tradeEstimated entry price $68.51, close on Wed Mar 12, 2025Current price $104.01, close on Tue Nov 10Mar 12, 2025Apr 10, 202529d
Ro KhannaStockPurchase$1,001 - $15,000+58.0% since the tradeEstimated entry price $65.81, close on Tue Nov 12, 2024Current price $104.01, close on Tue Nov 10Nov 12, 2024Dec 5, 202423d
Byron DonaldsStockSale$1,001 - $15,000+27.3% since the saleEstimated exit price $81.72, close on Fri Mar 5, 2021Current price $104.01, close on Tue Nov 10Mar 5, 2021Nov 8, 20241344d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in EW filterable by party, chamber, type and account.

STOCK Act2 members · estimate, as of Nov 10, 2026

Members of Congress reporting a position

2 members report a position (estimated).
MemberParty, chamberEstimated positionShare of their portfolio
Julie JohnsonDemocrat · House$15,001 - $50,0000.3%
Gilbert Ray Cisneros, Jr.Democrat · House$1,001 - $15,000<0.1%

The largest estimated position is in the $15,001 - $50,000 band. Estimate, as of Nov 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 11, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on EW show and how current they are.

Are insiders buying or selling EW?

Across the 20 most recent open-market filings shown here, 0 were purchases and 20 were sales. 9 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded EW?

Ro Khanna, Alan Armstrong, Josh Gottheimer, Jefferson Shreve, Bruce Westerman, Robert Bresnahan and others disclosed EW transactions in the filings shown here.

Which members of Congress hold EW?

2 members of Congress report a position in EW in the estimate we hold as of Nov 10, 2026. The estimated positions belong to Julie Johnson and Gilbert Ray Cisneros, Jr. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is EW in the S&P 500 or the Nasdaq 100?

Edwards Lifesciences Corporation is a current member of the S&P 500, per the membership list we hold as of Nov 11, 2026. Current members of either index get a page here whatever their filing history.

How quickly are EW trades disclosed?

Insider filings on this page reached the public a median of 0 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 30 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track